|
1
|
Nanavaty P, Alvarez MS and Alberts WM:
Lung cancer screening: Advantages, controversies, and applications.
Cancer Control. 21:9–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nasim F, Sabath BF and Eapen GA: Lung
cancer. Med Clin North Am. 103:463–473. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheung CHY and Juan HF: Quantitative
proteomics in lung cancer. J Biomed Sci. 24:372017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Sousa VML and Carvalho L: Heterogeneity
in lung cancer. Pathobiology. 85:96–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Syrigos KN, Saif MW, Karapanagiotou EM,
Oikonomopoulos G and De Marinis F: The need for third-line
treatment in non-small cell lung cancer: An overview of new
options. Anticancer Res. 31:649–659. 2011.PubMed/NCBI
|
|
7
|
Richard PJ and Rengan R: Oligometastatic
non-small-cell lung cancer: Current treatment strategies. Lung
Cancer (Auckl). 7:129–140. 2016.PubMed/NCBI
|
|
8
|
Hirsch FR, Suda K, Wiens J and Bunn PA Jr:
New and emerging targeted treatments in advanced non-small-cell
lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X
and Ta S: LncRNA HOXA-AS2 and its molecular mechanisms in human
cancer. Clin Chim Acta. 485:229–233. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng WX, Koirala P and Mo YY:
LncRNA-Mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feng H, Zhang J, Shi Y, Wang L, Zhang C
and Wu L: Long noncoding RNA LINC-PINT is inhibited in gastric
cancer and predicts poor survival. J Cell Biochem. 120:9594–9600.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duan J, Ma X, Shi J, Xuan Y, Wang H, Li P,
Zhang Y, Fan Y, Gong H, Ma X, et al: Long noncoding RNA LINC-PINT
promotes proliferation through EZH2 and predicts poor prognosis in
clear cell renal cell carcinoma. Onco Targets Ther. 12:4729–4740.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hong L, Wang H, Wang J, Wei S, Zhang F,
Han J, Liu Y, Ma M, Liu C, Xu Y and Jiang D: LncRNA PTCSC3 inhibits
tumor growth and cancer cell stemness in gastric cancer by
interacting with lncRNA linc-pint. Cancer Manag Res.
11:10393–10399. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei
P, Liu H, Xu J, Xiao F, Zhou H, et al: A peptide encoded by
circular form of LINC-PINT suppresses oncogenic transcriptional
elongation in glioblastoma. Nat Commun. 9:44752018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang L, Hu J, Li J, Yang Q, Hao M and Bu
L: Long noncoding RNA LINC-PINT inhibits non-small cell lung cancer
progression through sponging miR-218-5p/PDCD4. Artif Cells Nanomed
Biotechnol. 47:1595–1602. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang S, Jiang W, Zhang X, Lu Z, Geng Q,
Wang W, Li N and Cai X: LINC-PINT alleviates lung cancer
progression via sponging miR-543 and inducing PTEN. Cancer Med.
9:1999–2009. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chassagnon G, Bennani S and Revel MP: New
TNM classification of non-small cell lung cancer. Rev Pneumol Clin.
73:34–39. 2017.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Collins LG, Haines C, Perkel R and Enck
RE: Lung cancer: Diagnosis and management. Am Fam Physician.
75:56–63. 2007.PubMed/NCBI
|
|
22
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ,
Dobelbower M, et al: Non-Small cell lung cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Cancer
Netw. 15:504–535. 2017. View Article : Google Scholar
|
|
23
|
Gong HY, Wang Y, Han G and Song QB:
Radiotherapy for oligometastatic tumor improved the prognosis of
patients with non-small cell lung cancer (NSCLC). Thorac Cancer.
10:1136–1140. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jonna S and Subramaniam DS: Molecular
diagnostics and targeted therapies in non-small cell lung cancer
(NSCLC): An update. Discov Med. 27:167–170. 2019.PubMed/NCBI
|
|
25
|
Chen G, Umelo IA, Lv S, Teugels E, Fostier
K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Grève J:
MiR-146a inhibits cell growth, cell migration and induces apoptosis
in non-small cell lung cancer cells. PLoS One. 8:e603172013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Camidge DR, Doebele RC and Kerr KM:
Comparing and contrasting predictive biomarkers for immunotherapy
and targeted therapy of NSCLC. Nat Rev Clin Oncol. 16:341–355.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao P, Wang H, Yu J, Zhang J, Yang Z, Liu
M, Niu Y, Wei X, Wang W, Li H, et al: MiR-3607-3p suppresses
non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
PLoS Genet. 14:e10077902018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang SY, Li Y, Jiang YS and Li RZ:
Investigation of serum miR-411 as a diagnosis and prognosis
biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol
Sci. 21:4092–4097. 2017.PubMed/NCBI
|
|
29
|
Zhang G, Wang Q, Zhang X, Ding Z and Liu
R: LncRNA FENDRR suppresses the progression of NSCLC via regulating
miR-761/TIMP2 axis. Biomed Pharmacother. 118:1093092019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He R, Zhang FH and Shen N: LncRNA
FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through
suppressing E-cadherin and regulating WNT pathway in non-small cell
lung cancer (NSCLC). Biomed Pharmacother. 95:331–338. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang T, Li H, Chen T, Ren H, Shi P and
Chen M: LncRNA MALAT1 depressed chemo-sensitivity of NSCLC cells
through directly functioning on miR-197-3p/p120 catenin axis. Mol
Cells. 42:270–283. 2019.PubMed/NCBI
|
|
32
|
Liu W: LncRNA LINC-PINT inhibits cancer
cell proliferation, invasion, and migration in osteosarcoma by
downregulating miRNA-21. Cancer Biother Radiopharm. 34:258–263.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chao Y and Zhou D: lncRNA-D16366 is a
potential biomarker for diagnosis and prognosis of hepatocellular
carcinoma. Med Sci Monit. 25:6581–6586. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang N, Meng X, Mi H, Chi Y, Li S, Jin Z,
Tian H, He J, Shen W, Tian H, et al: Circulating lncRNA XLOC_009167
serves as a diagnostic biomarker to predict lung cancer. Clin Chim
Acta. 486:26–33. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xie Y, Zhang Y, Du L, Jiang X, Yan S, Duan
W, Li J, Zhan Y, Wang L, Zhang S, et al: Circulating long noncoding
RNA act as potential novel biomarkers for diagnosis and prognosis
of non-small cell lung cancer. Mol Oncol. 12:648–658. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang SH and O'Sullivan B: Overview of the
8th edition TNM classification for head and neck cancer. Curr Treat
Options Oncol. 18:402017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saffarzadeh AG, Blasberg JD and Beyond
TNM: Searching for new patient-centric prognostic indicators in
NSCLC. Ann Surg Oncol. 25:3425–3426. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou M, Zhang Z, Zhao H, Bao S, Cheng L
and Sun J: An immune-related six-lncRNA signature to improve
prognosis prediction of glioblastoma multiforme. Mol Neurobiol.
55:3684–3697. 2018.PubMed/NCBI
|
